N,N-Dimethyl-di-n-propylessigsaeureamid | 22635-29-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: N,N-Dimethyl-di-n-propylessigsaeureamid
• 英文别名: N,N-Dimethyl-2-propylvaleramide；N,N-dimethyl-2-propylpentanamide
• CAS: 22635-29-6
• 化学式: C₁₀H₂₁NO
• 分子量: 171.283
• InChiKey: FHUMZQPUJPSWLG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N,N-Dimethyl-di-n-propylessigsaeureamid 生成 dimethyl-(2-propyl-pentyl)-amine
  参考文献：
  名称：

  Benoit Guyod; Benoit Guyod; Simiand, European Journal of Medicinal Chemistry, 1974, vol. 9, # 2, p. 169 - 174

  摘要：

  DOI：
• 作为产物：
  描述：

  2,2-二-正丙基乙酰基氯 、 二甲胺 生成 N,N-Dimethyl-di-n-propylessigsaeureamid
  参考文献：
  名称：

  Benoit Guyod; Benoit Guyod; Simiand, European Journal of Medicinal Chemistry, 1974, vol. 9, # 2, p. 169 - 174

  摘要：

  DOI：

文献信息

• Methylidene oxazolidinone compound and preparation method thereof
  申请人：Korea Institute of Science and Technology

  公开号：US20040087633A1

  公开（公告）日：2004-05-06

  A methylidene oxazolidinone compound represented by formula (1) or a pharmaceutically acceptable salt thereof, and a preparation method thereof, showing superior antimicrobial activities against gram-positive germs including resistant strains such as methicillic-resistant staphylococcus aureus and vancomycin-resistant enterococcus: 1

  由化学式（1）表示的甲基亚胺噁唑啉酮化合物或其药用可接受的盐，以及其制备方法，对包括耐甲氧西林金黄色葡萄球菌和耐万古霉素肠球菌在内的革兰氏阳性细菌表现出卓越的抗菌活性。
• METAP2 Inhibitors and Methods of Treating Obesity
  申请人：SynDevRx, Inc.

  公开号：US20140308235A1

  公开（公告）日：2014-10-16

  The present invention relates to modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and/or treating metabolic syndrome utilizing the modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of improving insulin sensitivity and glycemic control, reducing insulin levels and/or improving leptin sensitivity utilizing the modified or polymer conjugated MetAP2 inhibitors.

  本发明涉及修饰或聚合的MetAP2抑制剂。本发明还涉及利用修饰或聚合的MetAP2抑制剂预防、诱导、引起或增加体重减轻，治疗肥胖和/或代谢综合征的方法。本发明还涉及利用修饰或聚合的MetAP2抑制剂改善胰岛素敏感性和血糖控制，降低胰岛素水平和/或改善瘦素敏感性的方法。
• METAP2 INHIBITORS AND METHODS OF TREATING OBESITY
  申请人：SynDevRx, Inc.

  公开号：US20150374657A1

  公开（公告）日：2015-12-31

  The present invention relates to modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and/or treating metabolic syndrome utilizing the modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of improving insulin sensitivity and glycemic control, reducing insulin levels and/or improving leptin sensitivity utilizing the modified or polymer conjugated MetAP2 inhibitors.

  本发明涉及改性或聚合物结合的MetAP2抑制剂。本发明还涉及利用改性或聚合物结合的MetAP2抑制剂预防、诱导、引起或增加体重减轻，治疗肥胖和/或代谢综合征的方法。本发明还涉及利用改性或聚合物结合的MetAP2抑制剂改善胰岛素敏感性和血糖控制，降低胰岛素水平和/或改善瘦素敏感性的方法。
• Potassium tert-Butoxide Facilitated Amination of Carboxylic Acids with N,N-Dimethylformamide
  作者：Jing Zhang、Yuanjing Huang

  DOI：10.1055/a-1817-1965

  日期：2022.8

  Herein a practical and efficient potassium tert-butoxide (KO t Bu)-facilitated amination of carboxylic acids with N,N-dimethylamine is described. In the presence of catalytic amount of KO t Bu, a variety of aliphatic and aromatic carboxylic acids are transformed to N,N-dimethylamides using DMF as the dimethylamine reagent with the assistance of trimethylacetic anhydride. The applicability of this protocol

  本文描述了一种实用且有效的叔丁醇钾 (KO t Bu)-促进羧酸与N , N-二甲胺的胺化。在催化量的 KO t Bu 存在下，在三甲基乙酸酐的帮助下，使用 DMF 作为二甲胺试剂，多种脂肪族和芳香族羧酸转化为N，N-二甲基酰胺。该协议的适用性通过复杂药物分子的后期二甲基酰胺化得到证明。涉及 KO t的似是而非的反应机制 在机理研究的基础上，提出了由甲酰胺分解和酸酐介导的缩合促进 Bu 促进的原位胺生成。
• NERVE REGENERATION PROMOTERS
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1685832A1

  公开（公告）日：2006-08-02

  A nerve regeneration which comprises a compound is represented by formula (I): (wherein all symbols are shown in the description), a salt thereof or a prodrug thereof. The compound of the present invention is suppresses nerve cell death as a substance for accelerating growth and/or differentiation of stem cells (nerve stem cells, embryonic stem cells, bone marrow cells, etc.), a substance for accelerating growth and/or differentiation of nerve precursor cells, a potentiator for neurotrophic factor activity, a neurotrophic factor-like substance or a neurodegenerative suppressor, and accelerates repair and regeneration of nerve tissues by neogenesis, regeneration and/or axon evolution. In addition, the compound of the present invention is useful for preparation from brain tissues, bone marrow and/or embryonic stem cells of cells for transplant (nerve stem cells, nerve precursor cells, nerve cells, etc.) and also accelerates grafting, growth, differentiation and/or function expression of cells for transplant whereupon it is useful for prevention and/or treatment of neurodegenerative diseases.

  由式 (I) 所表示的化合物组成的神经再生剂： (其中所有符号均在描述中显示）、其盐或其原药。本发明化合物可抑制神经细胞死亡，可作为加速干细胞（神经干细胞、胚胎干细胞、骨髓细胞等）生长和/或分化的物质、加速神经前体细胞生长和/或分化的物质、神经营养因子活性增效剂、神经营养因子样物质或神经退行性抑制剂，并通过新生、再生和/或轴突演化加速神经组织的修复和再生。此外，本发明的化合物可用于从脑组织、骨髓和/或胚胎干细胞中制备移植细胞（神经干细胞、神经前体细胞、神经细胞等），还可加速移植细胞的移植、生长、分化和/或功能表达，从而可用于预防和/或治疗神经退行性疾病。